{"gene":"GNB4","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2013,"finding":"GNB4 mutations (p.Gly53Asp and p.Lys89Glu) impair bradykinin-induced G-protein-coupled receptor (GPCR) signaling that is normally facilitated by wild-type Gβ4, establishing GNB4 as a positive regulator of GPCR signaling in peripheral nerve function.","method":"In vitro GPCR signaling assays with mutant vs. wild-type GNB4 constructs; immunohistochemistry showing Gβ4 localization in axons and Schwann cells of peripheral nerves and reduced expression in sural nerve of mutation carriers","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vitro functional assay with disease mutants plus localization data, single lab, two orthogonal methods","pmids":["23434117"],"is_preprint":false},{"year":2023,"finding":"H. pylori infection activates NF-κB, which upregulates TET1; TET1 binds the GNB4 promoter and demethylates it (particularly at CpG#5), increasing GNB4 expression; elevated GNB4 then drives oncogenic behavior via activation of the Hippo-YAP1 pathway (promoting YAP1 activity) in gastric cancer cells.","method":"Chromatin immunoprecipitation (ChIP), co-immunoprecipitation (Co-IP), methylation-specific PCR, pyrosequencing, mass spectrometry, western blotting, gain/loss-of-function assays (CCK-8, EdU, colony formation, transwell, xenograft), immunofluorescence","journal":"BMC medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in single lab including ChIP, Co-IP, and in vivo xenograft, but not independently replicated","pmids":["37016382"],"is_preprint":false},{"year":2024,"finding":"Silencing GNB4 in glioma cells activates the cGAS-STING pathway, which in turn induces pyroptosis (evidenced by increased pyroptosis-related protein expression and elevated inflammatory factors), thereby inhibiting glioma cell proliferation, migration, and invasion. A cGAS-STING inhibitor reversed these effects, placing GNB4 upstream of cGAS-STING-mediated pyroptosis.","method":"siRNA-mediated GNB4 silencing, western blotting, ELISA, cell viability/wound-healing/transwell assays, pathway inhibitor rescue experiments","journal":"Molecular biotechnology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pharmacological pathway inhibitor rescue without direct binding or reconstitution data","pmids":["38814382"],"is_preprint":false},{"year":2021,"finding":"miR-133b targets GNB4 mRNA (confirmed as a direct downstream target), suppressing its expression; overexpression of GNB4 reverses the pro-viability and pro-differentiation effects of miR-133b on osteoblasts, placing GNB4 downstream of miR-133b in the regulation of osteoblast differentiation.","method":"qRT-PCR, western blot, CCK-8 cell viability, flow cytometry apoptosis, osteoblast differentiation markers (ALP, Runx2, Osterix, OPN); luciferase target validation implied by 'identified and confirmed as a downstream target gene'","journal":"Biochemical genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, target confirmation methodology not fully detailed in abstract, no reconstitution or structural data","pmids":["33687637"],"is_preprint":false},{"year":2025,"finding":"Pathogenic GNB4 variants in CMT patients cluster in 3D space on the GNB4 protein structure, suggesting a structural basis for loss of function; affected residues map to the WD40 domain repeat region critical for Gβ function.","method":"3D structural mapping of known pathogenic variants, variant reclassification per ACMG guidelines, segregation analysis","journal":"Neurology. Genetics","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational/structural mapping without direct in vitro functional validation of the structural clustering","pmids":["41164122"],"is_preprint":false}],"current_model":"GNB4 encodes Gβ4, a guanine nucleotide-binding protein β-subunit that positively facilitates GPCR (e.g., bradykinin receptor) signaling in peripheral nerves; pathogenic mutations in its WD40 domain impair this GPCR signaling activity and cause dominant intermediate Charcot-Marie-Tooth disease, while in cancer contexts GNB4 can be epigenetically upregulated (via TET1-mediated promoter demethylation downstream of NF-κB/H. pylori) to activate Hippo-YAP1 oncogenic signaling, and its silencing engages the cGAS-STING/pyroptosis axis in glioma cells."},"narrative":{"mechanistic_narrative":"GNB4 encodes Gβ4, a guanine nucleotide-binding protein β-subunit that positively facilitates G-protein-coupled receptor signaling, demonstrated for bradykinin-induced GPCR signaling in peripheral nerve, where Gβ4 localizes to axons and Schwann cells [PMID:23434117]. Disease-associated missense mutations (p.Gly53Asp, p.Lys89Glu) impair this signaling activity, and pathogenic variants cluster spatially within the WD40 repeat region required for Gβ function, providing a structural rationale for loss of function that underlies dominant intermediate Charcot-Marie-Tooth disease [PMID:23434117, PMID:41164122]. Beyond its canonical signaling role, GNB4 expression is regulated in disease contexts: it is epigenetically upregulated in gastric cancer when H. pylori-driven NF-κB induces TET1, which demethylates the GNB4 promoter, and the resulting elevated GNB4 activates Hippo-YAP1 oncogenic signaling [PMID:37016382], while it is repressed by miR-133b during osteoblast differentiation [PMID:33687637].","teleology":[{"year":2013,"claim":"Established that GNB4 functions as a positive regulator of GPCR signaling and that disease mutations disrupt this activity, linking the gene to peripheral nerve function.","evidence":"In vitro bradykinin GPCR signaling assays comparing mutant and wild-type GNB4, with immunohistochemistry of peripheral nerve","pmids":["23434117"],"confidence":"Medium","gaps":["Specific GPCRs and downstream effectors engaged by Gβ4 in nerve not enumerated","Mechanism by which mutations alter Gβ4-Gγ or receptor coupling not resolved","Single lab, not independently replicated"]},{"year":2021,"claim":"Placed GNB4 downstream of a microRNA regulatory axis in bone, showing its expression is repressed by miR-133b during osteoblast differentiation.","evidence":"miR-133b target validation, GNB4 overexpression rescue, and osteoblast differentiation marker assays in cultured cells","pmids":["33687637"],"confidence":"Low","gaps":["Direct luciferase target confirmation not fully detailed","Signaling pathway through which GNB4 affects osteoblast fate unspecified","No in vivo validation"]},{"year":2023,"claim":"Defined an epigenetic regulatory cascade upregulating GNB4 in cancer and connected elevated GNB4 to Hippo-YAP1 oncogenic signaling.","evidence":"ChIP, methylation-specific PCR/pyrosequencing, Co-IP, gain/loss-of-function and xenograft assays in gastric cancer cells","pmids":["37016382"],"confidence":"Medium","gaps":["Molecular link between Gβ4 and YAP1 activation not mechanistically dissected","Whether GNB4's GPCR-subunit activity mediates the Hippo effect unknown","Single lab, not independently replicated"]},{"year":2024,"claim":"Positioned GNB4 upstream of the cGAS-STING/pyroptosis axis in glioma, indicating its silencing restrains tumor cell behavior.","evidence":"siRNA silencing with pharmacological cGAS-STING inhibitor rescue and proliferation/migration/invasion assays in glioma cells","pmids":["38814382"],"confidence":"Low","gaps":["No direct binding or reconstitution linking GNB4 to cGAS-STING","Mechanism by which GNB4 represses the pathway unknown","Pharmacological rescue only, single lab"]},{"year":2025,"claim":"Provided a structural framework for GNB4 loss of function by showing pathogenic CMT variants cluster within the WD40 repeat region.","evidence":"3D structural mapping of pathogenic variants, ACMG reclassification, and segregation analysis","pmids":["41164122"],"confidence":"Low","gaps":["Structural clustering not validated by direct in vitro functional assays","Effect of clustering on Gβ4 protein interactions not measured"]},{"year":null,"claim":"How Gβ4's canonical GPCR-coupled signaling activity relates mechanistically to its context-dependent roles in Hippo-YAP1, cGAS-STING, and osteoblast pathways remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unifying mechanism connecting Gβ4 signaling subunit function to its downstream cancer and differentiation effects","Direct effectors and binding partners of Gβ4 in non-neuronal contexts not identified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0]}],"localization":[],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9HAV0","full_name":"Guanine nucleotide-binding protein subunit beta-4","aliases":["Transducin beta chain 4"],"length_aa":340,"mass_kda":37.6,"function":"Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q9HAV0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GNB4","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"GNB1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/GNB4","total_profiled":1310},"omim":[{"mim_id":"615185","title":"CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE F; CMTDIF","url":"https://www.omim.org/entry/615185"},{"mim_id":"610863","title":"GUANINE NUCLEOTIDE-BINDING PROTEIN, BETA-4; GNB4","url":"https://www.omim.org/entry/610863"},{"mim_id":"607298","title":"GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-13; GNG13","url":"https://www.omim.org/entry/607298"},{"mim_id":"606482","title":"CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB","url":"https://www.omim.org/entry/606482"},{"mim_id":"139130","title":"GUANINE NUCLEOTIDE-BINDING PROTEIN, BETA-3; GNB3","url":"https://www.omim.org/entry/139130"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Golgi apparatus","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GNB4"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9HAV0","domains":[{"cath_id":"2.130.10.10","chopping":"45-338","consensus_level":"high","plddt":97.3584,"start":45,"end":338},{"cath_id":"1.20.5","chopping":"1-35","consensus_level":"medium","plddt":95.6789,"start":1,"end":35}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HAV0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HAV0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HAV0-F1-predicted_aligned_error_v6.png","plddt_mean":97.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GNB4","jax_strain_url":"https://www.jax.org/strain/search?query=GNB4"},"sequence":{"accession":"Q9HAV0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9HAV0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9HAV0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HAV0"}},"corpus_meta":[{"pmid":"23434117","id":"PMC_23434117","title":"Exome sequencing identifies GNB4 mutations as a cause of dominant intermediate Charcot-Marie-Tooth disease.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23434117","citation_count":43,"is_preprint":false},{"pmid":"37016382","id":"PMC_37016382","title":"Helicobacter pylori-induced aberrant demethylation and expression of GNB4 promotes gastric carcinogenesis via the Hippo-YAP1 pathway.","date":"2023","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37016382","citation_count":31,"is_preprint":false},{"pmid":"38154055","id":"PMC_38154055","title":"Plasma methylated GNB4 and Riplet as a novel dual-marker panel for the detection of hepatocellular carcinoma.","date":"2023","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/38154055","citation_count":22,"is_preprint":false},{"pmid":"28642160","id":"PMC_28642160","title":"A novel missense variant (Gln220Arg) of GNB4 encoding guanine nucleotide-binding protein, subunit beta-4 in a Japanese family with autosomal dominant motor and sensory neuropathy.","date":"2017","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28642160","citation_count":12,"is_preprint":false},{"pmid":"38617926","id":"PMC_38617926","title":"CircRNA circRREB1 promotes tumorigenesis and progression of breast cancer by activating Erk1/2 signaling through interacting with GNB4.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/38617926","citation_count":11,"is_preprint":false},{"pmid":"27908631","id":"PMC_27908631","title":"Confirmation of the GNB4 gene as causal for Charcot-Marie-Tooth disease by a novel de novo mutation in a Czech patient.","date":"2016","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/27908631","citation_count":11,"is_preprint":false},{"pmid":"34071515","id":"PMC_34071515","title":"Clinical and Neuroimaging Features in Charcot-Marie-Tooth Patients with GNB4 Mutations.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34071515","citation_count":10,"is_preprint":false},{"pmid":"33687637","id":"PMC_33687637","title":"MiR-133b Modulates the Osteoblast Differentiation to Prevent Osteoporosis Via Targeting GNB4.","date":"2021","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33687637","citation_count":8,"is_preprint":false},{"pmid":"38814382","id":"PMC_38814382","title":"GNB4 Silencing Promotes Pyroptosis to Inhibit the Development of Glioma by Activating cGAS-STING Pathway.","date":"2024","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/38814382","citation_count":7,"is_preprint":false},{"pmid":"35170486","id":"PMC_35170486","title":"Disrupting circ-GNB4 mitigates high glucose-induced human mesangial cells injury by regulating the proliferation, ECM accumulation, inflammation and oxidative stress through circ-GNB4/miR-23c/EGR1 pathway [RETRACTED].","date":"2022","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35170486","citation_count":6,"is_preprint":false},{"pmid":"41164122","id":"PMC_41164122","title":"Novel GNB4 Gene Variant and the Spectrum of GNB4 Variants in Patients With Charcot-Marie-Tooth Disease.","date":"2025","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41164122","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8520,"output_tokens":1440,"usd":0.02358,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8121,"output_tokens":1917,"usd":0.044265,"stage2_stop_reason":"end_turn"},"total_usd":0.067845,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"GNB4 mutations (p.Gly53Asp and p.Lys89Glu) impair bradykinin-induced G-protein-coupled receptor (GPCR) signaling that is normally facilitated by wild-type Gβ4, establishing GNB4 as a positive regulator of GPCR signaling in peripheral nerve function.\",\n      \"method\": \"In vitro GPCR signaling assays with mutant vs. wild-type GNB4 constructs; immunohistochemistry showing Gβ4 localization in axons and Schwann cells of peripheral nerves and reduced expression in sural nerve of mutation carriers\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vitro functional assay with disease mutants plus localization data, single lab, two orthogonal methods\",\n      \"pmids\": [\"23434117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"H. pylori infection activates NF-κB, which upregulates TET1; TET1 binds the GNB4 promoter and demethylates it (particularly at CpG#5), increasing GNB4 expression; elevated GNB4 then drives oncogenic behavior via activation of the Hippo-YAP1 pathway (promoting YAP1 activity) in gastric cancer cells.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), co-immunoprecipitation (Co-IP), methylation-specific PCR, pyrosequencing, mass spectrometry, western blotting, gain/loss-of-function assays (CCK-8, EdU, colony formation, transwell, xenograft), immunofluorescence\",\n      \"journal\": \"BMC medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in single lab including ChIP, Co-IP, and in vivo xenograft, but not independently replicated\",\n      \"pmids\": [\"37016382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Silencing GNB4 in glioma cells activates the cGAS-STING pathway, which in turn induces pyroptosis (evidenced by increased pyroptosis-related protein expression and elevated inflammatory factors), thereby inhibiting glioma cell proliferation, migration, and invasion. A cGAS-STING inhibitor reversed these effects, placing GNB4 upstream of cGAS-STING-mediated pyroptosis.\",\n      \"method\": \"siRNA-mediated GNB4 silencing, western blotting, ELISA, cell viability/wound-healing/transwell assays, pathway inhibitor rescue experiments\",\n      \"journal\": \"Molecular biotechnology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pharmacological pathway inhibitor rescue without direct binding or reconstitution data\",\n      \"pmids\": [\"38814382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-133b targets GNB4 mRNA (confirmed as a direct downstream target), suppressing its expression; overexpression of GNB4 reverses the pro-viability and pro-differentiation effects of miR-133b on osteoblasts, placing GNB4 downstream of miR-133b in the regulation of osteoblast differentiation.\",\n      \"method\": \"qRT-PCR, western blot, CCK-8 cell viability, flow cytometry apoptosis, osteoblast differentiation markers (ALP, Runx2, Osterix, OPN); luciferase target validation implied by 'identified and confirmed as a downstream target gene'\",\n      \"journal\": \"Biochemical genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, target confirmation methodology not fully detailed in abstract, no reconstitution or structural data\",\n      \"pmids\": [\"33687637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Pathogenic GNB4 variants in CMT patients cluster in 3D space on the GNB4 protein structure, suggesting a structural basis for loss of function; affected residues map to the WD40 domain repeat region critical for Gβ function.\",\n      \"method\": \"3D structural mapping of known pathogenic variants, variant reclassification per ACMG guidelines, segregation analysis\",\n      \"journal\": \"Neurology. Genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational/structural mapping without direct in vitro functional validation of the structural clustering\",\n      \"pmids\": [\"41164122\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GNB4 encodes Gβ4, a guanine nucleotide-binding protein β-subunit that positively facilitates GPCR (e.g., bradykinin receptor) signaling in peripheral nerves; pathogenic mutations in its WD40 domain impair this GPCR signaling activity and cause dominant intermediate Charcot-Marie-Tooth disease, while in cancer contexts GNB4 can be epigenetically upregulated (via TET1-mediated promoter demethylation downstream of NF-κB/H. pylori) to activate Hippo-YAP1 oncogenic signaling, and its silencing engages the cGAS-STING/pyroptosis axis in glioma cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GNB4 encodes Gβ4, a guanine nucleotide-binding protein β-subunit that positively facilitates G-protein-coupled receptor signaling, demonstrated for bradykinin-induced GPCR signaling in peripheral nerve, where Gβ4 localizes to axons and Schwann cells [#0]. Disease-associated missense mutations (p.Gly53Asp, p.Lys89Glu) impair this signaling activity, and pathogenic variants cluster spatially within the WD40 repeat region required for Gβ function, providing a structural rationale for loss of function that underlies dominant intermediate Charcot-Marie-Tooth disease [#0, #4]. Beyond its canonical signaling role, GNB4 expression is regulated in disease contexts: it is epigenetically upregulated in gastric cancer when H. pylori-driven NF-κB induces TET1, which demethylates the GNB4 promoter, and the resulting elevated GNB4 activates Hippo-YAP1 oncogenic signaling [#1], while it is repressed by miR-133b during osteoblast differentiation [#3].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Established that GNB4 functions as a positive regulator of GPCR signaling and that disease mutations disrupt this activity, linking the gene to peripheral nerve function.\",\n      \"evidence\": \"In vitro bradykinin GPCR signaling assays comparing mutant and wild-type GNB4, with immunohistochemistry of peripheral nerve\",\n      \"pmids\": [\"23434117\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific GPCRs and downstream effectors engaged by Gβ4 in nerve not enumerated\", \"Mechanism by which mutations alter Gβ4-Gγ or receptor coupling not resolved\", \"Single lab, not independently replicated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed GNB4 downstream of a microRNA regulatory axis in bone, showing its expression is repressed by miR-133b during osteoblast differentiation.\",\n      \"evidence\": \"miR-133b target validation, GNB4 overexpression rescue, and osteoblast differentiation marker assays in cultured cells\",\n      \"pmids\": [\"33687637\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Direct luciferase target confirmation not fully detailed\", \"Signaling pathway through which GNB4 affects osteoblast fate unspecified\", \"No in vivo validation\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined an epigenetic regulatory cascade upregulating GNB4 in cancer and connected elevated GNB4 to Hippo-YAP1 oncogenic signaling.\",\n      \"evidence\": \"ChIP, methylation-specific PCR/pyrosequencing, Co-IP, gain/loss-of-function and xenograft assays in gastric cancer cells\",\n      \"pmids\": [\"37016382\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between Gβ4 and YAP1 activation not mechanistically dissected\", \"Whether GNB4's GPCR-subunit activity mediates the Hippo effect unknown\", \"Single lab, not independently replicated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Positioned GNB4 upstream of the cGAS-STING/pyroptosis axis in glioma, indicating its silencing restrains tumor cell behavior.\",\n      \"evidence\": \"siRNA silencing with pharmacological cGAS-STING inhibitor rescue and proliferation/migration/invasion assays in glioma cells\",\n      \"pmids\": [\"38814382\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct binding or reconstitution linking GNB4 to cGAS-STING\", \"Mechanism by which GNB4 represses the pathway unknown\", \"Pharmacological rescue only, single lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Provided a structural framework for GNB4 loss of function by showing pathogenic CMT variants cluster within the WD40 repeat region.\",\n      \"evidence\": \"3D structural mapping of pathogenic variants, ACMG reclassification, and segregation analysis\",\n      \"pmids\": [\"41164122\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Structural clustering not validated by direct in vitro functional assays\", \"Effect of clustering on Gβ4 protein interactions not measured\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How Gβ4's canonical GPCR-coupled signaling activity relates mechanistically to its context-dependent roles in Hippo-YAP1, cGAS-STING, and osteoblast pathways remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying mechanism connecting Gβ4 signaling subunit function to its downstream cancer and differentiation effects\", \"Direct effectors and binding partners of Gβ4 in non-neuronal contexts not identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":2,"faith_total":3,"faith_pct":66.66666666666667}}